The recommendation of this product should be preferentially based on clinical observation and inventory of risk factors rather than based on costly and variable blood tests
A formal Phase 2 trial was completed in 2009, but over 15 years later, the results have never been published, another major red flag suggesting it failed to prove effective or safe
Hall KD, Ayuketah A, Brychta R, et al
[cite_start]Intranasal administration specifically bypasses first-pass hepatic metabolism and the blood-brain barrier (BBB) via olfactory and trigeminal nerve pathways[cite: 396]
Ruan Y, Jiang S, Musayeva A, Gericke A
Cell-based assays have been used to study GHK-Cu's relationship with VEGF and related angiogenic factors, exploring the compound's role in vascular biology research models